The state-of-the-art Pirche platform combines genetic typing with real-time AI-supported immunological simulations of protein-protein interactions, providing precise, personalized medical decision support in the fields of transplant medicine and immunotherapy to Nephrology, Oncology and Leukemia specialists. The fully digital technology relies on standard wet test results performed in clinical labs that are already standard of care. Pirche is connected through APIs with the IT systems of the leading laboratory service providers and is ‘PLUG AND PLAY’.
Our AI-supported technological platform allows physicians and specialists in the above three fields to make informed decisions on the transplant interventions necessary or — for the patients suffering from cancer — their best suited treatment plans, based on their genetic make-up. The medical evidence of the technology is proven with 55+ peer reviewed publications on 200,000+ patient cases. With Pirche, patients have improved outcomes, fewer complications and a better quality of life; payers can expect less expenses per patient and hospitals can improve their transplantation outcomes and cancer treatment success rates.
Pirche’s proprietary technology is protected in the USA, EU and other countries by 25 issued patents with additional patents pending. Pirche additionally owns the exclusive commercial rights for Linked Recognition, the sequential interaction of B-Cell and T-Cell Epitope Matching, globally and for all applications.
It is our strategy to provide the Pirche web platform through SaaS agreements and by partnering with the industry. More than 850 leading clinics worldwide are already registered users of the platform and Pirche has running contracts with the top tier service providers of HLA typing and antibody analysis diagnostics worldwide. Furthermore, Pirche has become a corner partner of government backed research in the EU, Germany and Canada.
Pirche AG is a German privately held joint-stock company (Aktiengesellschaft) founded in Berlin by Thomas Klein whose management possesses a track record over the past 25 years in biotechnology, bioinformatics and IT. The basic scientific work for this groundbreaking technology was done at the University Medical Center Utrecht (UMCU) in The Netherlands by Dr. Eric Spierings and his team.
P.S. In case you’ve been wondering what Pirche stands for, here’s the answer: Predicted Indirectly ReCognizable HLA Epitopes.